Burning Rock Announces Results of 2022 Annual General Meeting
September 08 2022 - 3:56AM
Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or
“Burning Rock”), a company focusing on the application of next
generation sequencing (NGS) technology in the field of precision
oncology, today announced that all shareholder resolutions proposed
at the Company’s 2022 annual general meeting held today were duly
passed. Specifically, the shareholders passed the following
resolutions approving:
- the ratification of the appointment
of Ernst & Young Hua Ming LLP as auditor of the Company for the
fiscal year ending December 31, 2022 and the authorization for the
directors of the Company to determine the remuneration of the
auditor;
- the re-election of Feng Deng, Leo
Li and Licen Lisa Xu as directors of the Company;
- the approval, confirmation and
ratification of the adoption of the 2022 Long-term Equity Incentive
Plan and the grant of options thereunder, the vesting of which is
tied to the Company’s future stock performances; and
- the authorization of each of the
directors of the Company to take any and all action that might be
necessary to effect the foregoing resolutions as such director, in
his or her absolute discretion, thinks fit.
About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to
guard life via science, focuses on the application of next
generation sequencing (NGS) technology in the field of precision
oncology. Its business consists of i) NGS-based therapy selection
testing for late-stage cancer patients, and ii) cancer early
detection, which has moved beyond proof-of-concept R&D into the
clinical validation stage.
For more information about Burning Rock, please visit:
www.brbiotech.com.
Safe Harbor Statement
This press release contains forward-looking statements. These
statements constitute “forward-looking” statements within the
meaning of Section 21E of the Securities Exchange Act of 1934, as
amended, and as defined in the U.S. Private Securities Litigation
Reform Act of 1995. These forward-looking statements can be
identified by terminology such as “will,” “expects,” “anticipates,”
“future,” “intends,” “plans,” “believes,” “estimates,” “target,”
“confident” and similar statements. Burning Rock may also make
written or oral forward-looking statements in its periodic reports
to the SEC, in its annual report to shareholders, in press releases
and other written materials and in oral statements made by its
officers, directors or employees to third parties. Statements that
are not historical facts, including statements about Burning Rock’s
beliefs and expectations, are forward-looking statements. Such
statements are based upon management’s current expectations and
current market and operating conditions, and relate to events that
involve known or unknown risks, uncertainties and other factors,
all of which are difficult to predict and many of which are beyond
Burning Rock’s control. Forward-looking statements involve risks,
uncertainties and other factors that could cause actual results to
differ materially from those contained in any such statements. All
information provided in this press release is as of the date of
this press release, and Burning Rock does not undertake any
obligation to update any forward-looking statement as a result of
new information, future events or otherwise, except as required
under applicable law.
Contact: IR@brbiotech.com
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Burning Rock Biotech (NASDAQ:BNR)
Historical Stock Chart
From Jul 2023 to Jul 2024